Marieke Vollebergh

Feb 23, 2024 | ejso.com | Steven Taylor |Liudmila L. Kodach |Jolanda van Dieren |Ignace de Hingh |Steven L. Taylor |Bas PL Wijnhoven | +3 more

Background: The clinical significance of tumour positive peritoneal cytology (CYT+) in patients with gastric cancer (GC) is unclear and therefore managed differently worldwide. The objectives of this study using nationwide data from the Netherlands Cancer Registry (NCR) were 1. to assess the frequency of cytological analysis at staging laparoscopy in GC patients, 2. to estimate the prevalence of CYT+ GC and 3.

Feb 21, 2023 | ejso.com | Marieke Vollebergh |Valesca P. Retèl |Misha D.P. Luyer |Bas PL Wijnhoven |Epidemiology HTA

Background: Prognosis of synchronous peritoneal metastasis (PM) in gastric cancer patients is very poor, with a median overall survival of 4 months. Palliative systemic chemotherapy is the standard treatment for gastric cancer patients with PM in the Netherlands. There are no potentially curative treatment options. PM, in contrast to lymphatic and haematogenous dissemination, should be regarded as locoregional extension of disease.

Feb 21, 2023 | ejso.com | Johanna van Sandick |Jolanda van Dieren |Marieke Vollebergh |Myriam Chalabi

Background: In gastric cancer (GC) patients HER2 is the only widely used predictive biomarker implemented in guidelines for metastatic patients. With recent successes in immunotherapy (IT) in upper GI malignancies, mismatch repair (MMR), Epstein-Barr Virus (EBV) testing and PD-L1 CPS (combined positive score) have become more important. However, most data on immunotherapy and biomarkers in gastric cancer originate from retrospective studies on selected patient populations.